Parkman Healthcare Partners LLC Buys 4,753 Shares of Insulet Corporation $PODD

Key Points

• Parkman Healthcare Partners LLC increased its stake in Insulet Corporation (NADSAQ:PODD) by 3.8%, making it the firm's largest position with a value of approximately $34.27 million.
• Insulet recently reported earnings of $1.17 per share for the last quarter, exceeding estimates and marking a 32.9% revenue increase year-over-year.
• Analysts have positive sentiments about Insulet, with multiple firms raising their target price to $350 and a consensus rating of "Moderate Buy".

Parkman Healthcare Partners LLC lifted its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 3.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 130,514 shares of the medical instruments supplier's stock after purchasing an additional 4,753 shares during the period. Insulet comprises 4.1% of Parkman Healthcare Partners LLC's portfolio, making the stock its largest position. Parkman Healthcare Partners LLC owned 0.19% of Insulet worth $34,274,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its position in shares of Insulet by 55.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock worth $1,376,000 after purchasing an additional 1,867 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Insulet by 85.1% during the first quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock worth $236,000 after purchasing an additional 412 shares in the last quarter. QRG Capital Management Inc. increased its stake in shares of Insulet by 75.6% in the first quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier's stock worth $533,000 after buying an additional 874 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Insulet by 225.4% in the first quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock worth $408,000 after buying an additional 1,075 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its stake in shares of Insulet by 2.6% in the first quarter. State of Alaska Department of Revenue now owns 8,212 shares of the medical instruments supplier's stock worth $2,156,000 after buying an additional 210 shares during the last quarter.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company's stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by company insiders.

Insulet Stock Performance

Shares of NASDAQ:PODD traded up $3.26 during trading on Tuesday, reaching $352.82. 656,705 shares of the company's stock traded hands, compared to its average volume of 544,344. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet Corporation has a 12 month low of $217.82 and a 12 month high of $353.50. The company has a 50 day moving average of $309.32 and a 200-day moving average of $290.77. The stock has a market capitalization of $24.83 billion, a P/E ratio of 107.24, a price-to-earnings-growth ratio of 2.90 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same quarter in the prior year, the firm earned $0.55 EPS. The company's revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

Analysts Set New Price Targets

PODD has been the subject of a number of research analyst reports. Sanford C. Bernstein restated an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. The Goldman Sachs Group initiated coverage on shares of Insulet in a research note on Friday, May 30th. They issued a "buy" rating and a $380.00 price target for the company. Royal Bank Of Canada lifted their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Canaccord Genuity Group lifted their price target on shares of Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Finally, Oppenheimer lifted their price target on shares of Insulet from $324.00 to $365.00 and gave the stock an "outperform" rating in a research note on Monday. Sixteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and an average target price of $335.12.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.